This suggests that FGFR2 might have a broad effect promoting IDC progression towards estrogen-independent basal-like phenotype and application of FGFR inhibitors could increase tumour sensitivity to anti-ER therapies [100]. The gene discussed is ESR1; the disease is neoplasm.